3-MeO-PCP

3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. It acts principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor and is additionally reported to inhibit monoamine reuptake, giving it a more stimulating and dopaminergic character than ketamine; the closely related analogs 4-MeO-PCP and 3-MeO-PCMo have been shown to engage the mesolimbic dopamine pathway to produce rewarding and reinforcing effects. It is considerably more potent and longer-acting than ketamine, which contributes to a narrow margin between recreational and toxic exposure. The compound has been implicated in numerous non-fatal intoxications and deaths, and its metabolism and analytical detection have been characterized in forensic casework and in silico ADME studies. Because standard phencyclidine immunoassays detect it inconsistently, laboratory confirmation generally relies on chromatographic and mass-spectrometric methods.